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Historically, biomedical research has been based on two
paradigms. First, measurements of biological behaviors
have been based on bulk assays that average over large
populations. Second, these behaviors have then been
crudely perturbed by systemic administration of thera-
peutic treatments. Nanotechnology has the potential to
transform these paradigms by enabling exquisite struc-
tures comparable in size with biomolecules as well as
unprecedented chemical and physical functionality at
small length scales. Here, we review nanotechnology-
based approaches for precisely measuring and perturbing
living systems. Remarkably, nanotechnology can be used
to characterize single molecules or cells at extraordi-
narily high throughput and deliver therapeutic payloads
to specific locations as well as exhibit dynamic bio-
mimetic behavior. These advances enable multimodal
interfaces that may yield unexpected insights into sys-
tems biology as well as new therapeutic strategies for
personalized medicine.
In the context of biology and medicine, nanotechnology
encompasses the materials, devices, and systems whose
structure and function are relevant for small length scales,
from nanometers (109 m) through microns (106 m)
(Whitesides 2003). This size regime is associated with
intriguing phenomena in both living systems and artifi-
cial devices. In particular, the fundamental building
blocks of life fall within this range, including biological
macromolecules and cells. For example, dsDNA is a
chain-like macromolecule with a diameter of 2 nm, cell
membranes are sheet-like structures with a thickness
of ;10 nm, and (suspended) eukaryotic cells are approx-
imately spherical with a diameter of ;10 um. Remark-
ably, artificial nanostructures can also be constructed with
comparable dimensions, including nanopores with;2-nm
openings, inorganic nanowires of ;10-nm diameter, and
spherical nanoparticles of 10- to 100-nm diameter (Box 1).
Moreover, this size regime is associated with unexpected
chemistry and physics where molecular effects can play a
significant role. This can be understood from a purely
geometric argument—a width of;10 nm in a silicon nano-
wire corresponds to only;40 atoms. A consequence of this
is that the surface area of these nanostructures is extremely
large relative to the volume. If the same silicon nanowire
has a square cross-section, then approximately one out of
every 10 atoms is associated with the surface. In contrast,
if we have amacroscopic wire with a width of 10mm, only
one in 10,000 atoms is associated with the surface. Finally,
as a consequence of these small dimensions, electrons are
spatially confined, resulting in exceptional electrical,
magnetic, optical, and thermal properties (Alivisatos
2004). An exciting prospect is to bridge across these
biomolecular and physical realms, leveraging unique ca-
pabilities from one realm for application in the other.
A conceptual framework for nano–bio interfaces can be
structured based on two overarching themes (Fig. 1). First,
nanotechnology enables new ways to measure and detect
biology both in vitro and in vivo. For instance, nanoscale
devices can sense minute differences at the level of single
molecules and single cells. This exquisite sensitivity can
be used, for instance, to characterize single-cell hetero-
geneity at extremely high throughput, revealing distinct
hierarchies and subpopulations. This level of detail is often
lost in traditional bulk assays, which measure ‘‘average’’
information about populations pooled from large num-
bers. Second, nanotechnology enables new ways to per-
turb cells and treat patients. For example, nanomaterials
can be designed to precisely deliver therapeutics to
targeted locations while overcoming or evading biological
barriers, thus altering the inherent pharmacokinetics and
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biodistribution of the cargo (typically a drug). This avoids
the complications associated with conventional delivery
using soluble drugs, which are associated with low and
inconsistent uptake. An exciting prospect is the syner-
gistic integration of these two themes: nanotechnologies
that can simultaneously detect and perturb biology. The
design and construction of such biomimetic nanosystems,
driven by feedback between nanomaterials and their
environment, will give rise to emergent behaviors such
as adaptation, self-organization, and amplification. These
capabilities are potentially transformative for confronting
the spatial and temporal complexity of living systems.
In this review, we review some illustrative examples of
nanotechnology applied to biology and medicine. This is
intended to make the new capabilities of nanotechnology
accessible for nonexperts (Box1, Fig. 2), with particular
emphasis on our respective areas of expertise in nano-
technology andmicrofluidics for mammalian cell biology
and medicine. In particular, we address recent advances
for characterizing biological systems: precision measure-
ment of biomolecules and cells in vitro, manipulation of
picoliter droplets, and the clinical evaluation of complex
samples. We also examine innovative approaches for per-
turbing biological systems, including minimally invasive
nanoneedles as well as rationally designed multifunc-
tional nanoparticles. Due to space constraints, we only
included a limited sampling of recent developments; we
refer readers to more comprehensive reviews elsewhere
for each topic. Finally, we consider the future prospects
and challenges for these technologies.
Counting one by one: precision measurements
of biomolecules and cells
Historically, measurements of biomolecules and cells
have occurred using bulk assays, such as lysates pooled
Box 1. Some assembly required: making nanostructures from molecular building blocks
The production of nanostructures occurs
through two general approaches (Madou
2012): (1) Top-down approaches impose
a structure or pattern on a flat surface by
successively adding or removing thin
layers of materials. For example, photoli-
thography uses UV light to pattern light-
sensitive polymer into nanoscale features.
Increased resolution can be achieved us-
ing electron or focused ion beams to
pattern surfaces, particularly to mill or
sculpt away material. (2) Bottom-up ap-
proaches are based on organizing atomic
or molecular components into hierar-
chical assemblies. For instance, cyto-
skeletal polymers form through the
sequential addition of monomeric pro-
tein units. Instead, carbon nanotubes or
silicon nanowires are grown from chem-
ical precursors in a gas or liquid phase. A
key conceptual difference is that top-
down fabrication is deterministic and well
controlled, whereas bottom-up assembly
is stochastic and may result in defects.
Nevertheless, top-down fabrication is
optimized for highly specific processing
conditions that are incompatible with
biologics, necessitating the use of bottom-
up assembly.
A particularly exciting example of
bottom-up self-assembly has been the
use of one-dimensional (1D) nucleic acid
strands that organize into designed two-
dimensional (2D) and three-dimensional
(3D) architectures based on molecular
recognition (Aldaye et al. 2008). Initial
work based on the formation of branches
and junctions inspired the design of 2D
tiles that organized into hierarchical lat-
tices based on logical rules (Seeman
2003). Subsequently, in ‘‘DNA origami,’’
a single long DNA strand could be guided
with shorter ‘‘staple’’ strands to fold into
more complex 2D shapes (Rothemund
2006). Most recently, these approaches
have been extended to 3D structures.
For instance, cuboidal ‘‘Lego-like’’ bricks
have been produced, where the free ends
are recognition sites that can bind
uniquely to particular bricks in solution
with a defined orientation (Fig. 2A; Ke
et al. 2012). Nearly arbitrary ‘‘pixelated’’
objects can be designed by removing
brick-like elements from a solid cube of
;10 pixels per side (;25 nm), with 100
different geometries demonstrated. Alter-
natively, DNA strands can be woven into
sheet-like structures that can be rolled,
curved, and twisted (Fig. 2B; Dietz et al.
2009). One promising application for
these techniques is to construct scaffolds
where DNA-linked proteins, peptides,
and inorganic nanostructures can be pre-
cisely positioned and dynamically actu-
ated. Building on these concepts, a drug
delivery ‘‘robot’’ has been demonstrated
where logical aptamer recognition of can-
cer-associated antigens led to unveiling of
antibody fragments that could molecu-
larly interact with cell surface receptors
(Douglas et al. 2012). Overall, DNA
nanotechnology is extremely powerful
for rationally designing 2D and 3D
nanostructures with precise control that
cannot be achieved using any other tech-
niques. Nevertheless, a continuing chal-
lenge is to reduce the formation of
defective and misfolded structures as well
as establish the biocompatibility of these
structures in vivo (Shih and Lin 2010).
A number of hybrid schemes have been
developed that combine top-down and
bottom-up approaches. For instance, in
soft lithography, top-down features are
replicated into plastic ‘‘stamps,’’ which
can be coated with proteins or inorganic
nanomaterials to be transferred to specific
locations on a surface (Whitesides et al.
2001). A variation of this approach
(PRINT) has been used tomake polymeric
particles, which are cast and removed
using roll-to-roll manufacturing (Wang
et al. 2011a). This approach can indepen-
dently control particle size, shape, stiff-
ness, material, and surface chemistry
(Fig. 2C). This was used to systematically
explore design rules for red blood cell-
shaped particles, showing that eightfold
softer particles displayed 30-fold en-
hanced circulation times (Merkel et al.
2011). Another example is the use of
photolithography to cross-link hydro-
gels in microfluidic channels, allowing
for layered composite architectures based
on interfacial flows (Helgeson et al. 2011).
This approach is particularly powerful for
constructing complex geometries with
different functionalities (Fig. 2D); for in-
stance, multicompartment particles with
barcode identifiers and regions of distinct
nucleic acid probes for multiplexed ana-
lyte detection (Pregibon et al. 2007). This
functionality could be further applied to
generate heterogeneous textures, chemi-
cal patchiness, and continuous molecular
gradients. Overall, these hybrid schemes
take advantage of both bottom-up and
top-down approaches for preparing nano-
structures with greater consistency under
more biocompatible conditions. However,
a continuing challenge for widespread
adoption will be to scale production for
high-volume manufacturing.
Wong et al.
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from populations of thousands or millions of cells at the
completion of the experiment. Instead, the small sizes
associated with nanostructures enable them to probe and
manipulate the dynamics of single cells and molecules
with unprecedented resolution. One example of this is
the use of nanoscale pores that can discriminate between
molecules on the basis of size and biochemical charac-
teristics (Branton et al. 2008). In particular, biological
channels and pores are capable of regulating ion transport
with a selectivity on the order of angstroms (0.1 nm or
1010 m) (Bayley and Cremer 2001). Inspired by this
biological functionality, it has been hypothesized that
nanopores could unwind and unzip DNA so that individ-
ual nucleotides translocate sequentially in single file.
Nevertheless, building precisely controlled pores with
;1-nm diameter has been challenging (Venkatesan and
Bashir 2011). Biological protein pores such as a-haemolysin
(aHL) present well-defined apertures but generally require
incorporation into mechanically delicate lipid bilayers to
maintain stability. In contrast, artificial nanopores lack the
chemical complexity of proteins and exhibit reduced
selectivity. A hybrid scheme was recently implemented
by directly inserting an aHL protein into a slightly larger
inorganic nanopore (Fig. 3A; Hall et al. 2010). This scheme
displays the benefits of a biological pore with increased
selectivity and sensitivity but also the mechanical stabil-
ity of an inorganic scaffold. This device could potentially
be scaled so that large numbers of nanopores could operate
in parallel. In principle, this approach could enable long
reads of single molecules at high translocation velocities.
An ongoing challenge for this technology is to achieve
sensitivity with single-base-pair resolution due to the
stochastic motion of DNA as well as the measurement
sensitivity at fast translocation speeds.
The small sizes of nanostructure-based biosensors can
be harnessed most effectively when they are patterned at
high densities around single cells, enabling highly local-
ized measurements at submicron and subcellular length
scales. For example, existing technologies cannot mea-
sure the cellular secretion of growth factors, cytokines,
and other signaling molecules into extracellular space
Figure 2. (A) DNA ‘‘Lego-like’’ bricks for three-dimensional cuboid structures. (B) DNA sheets assembled into curved and anisotropic
geometries. (C) Nanoparticles of different materials, shapes, and sizes fabricated using PRINT. (D) Multicomponent barcoded particles
fabricated using flow lithography. From Pregibon et al. (2007) and Ke et al. (2012). Reprinted with permission from AAAS. Reprinted
from Shih and Lin (2010), with permission from Elsevier. Reprinted from Wang et al. (2011a);  2011 Wiley-VCH Verlag GmbH & Co.,
KGaA, Weinheim.
Figure 1. Key themes underlying nanotechnology in biology
and medicine, including new capabilities to measure or perturb
cells in vitro as well as diagnose or treat patients. An exciting
prospect is the future integration of these different capabilities
for biomimetic behaviors such as adaption, self-organization,
and amplification.
Nanotechnology for biomedicine
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(Love 2010). Nanostructures are advantageous not only
because they are comparable in size with biomolecules
but also because their size enables enhanced optical
characteristics (Brolo 2012). One recent study used carbon
nanotube sensors to detect reactive oxygen species (ROS)
with single-molecule resolution based on optical fluores-
cence quenching (Jin et al. 2010). In response to epidermal
growth factor (EGF) stimulation of A431 carcinoma cells,
transient ‘‘hot spots’’ of high ROS concentration were
observed in the proximity of the cell membrane (Fig. 3B)
even when cells were fixed. An analogous approach was
used to measure intracellular cytochrome C dynamics
using plasmonic spectroscopy of gold nanoparticles (Choi
et al. 2009). Remarkably, in response to proapoptotic
stimuli, they were able to measure the release of cyto-
chrome C from mitochrondria into the cytoplasm. Finally,
an array of nanoplasmonic resonators patterned with sub-
micron spacing was used to characterize the autocrine
signaling of IL-2 in T lymphocytes, revealing a highly
localized secretion profile (Wang et al. 2011c). Overall,
these optical nanostructures enable exquisite molecular
sensitivity with high spatial and temporal resolution,
capable of distinguishing between molecules secreted by
a particular cell and those in the background. Nevertheless,
producing these nanostructures requires specialized fabrica-
tion techniques that are challenging to scale up, which will
need to be addressed before they can be widely used.
Another readout of interest for single cells is electrical
and ion channel activity. Such elecrophysiological mea-
surements are highly relevant for neuroscience (Alivisatos
et al. 2013) as well as pharmacological testing (Dunlop
et al. 2008). Nevertheless, existing patch clamps and
electrodes are relatively bulky and cumbersome so that
they integrate poorly with three-dimensional (3D) tissues
and do not achieve single-cell resolution. Nanostructures
add new capabilities here, since their high surface area to
volume ratios make them extremely sensitive to elec-
trical changes. There has been extensive work to develop
integrated circuits that are highly flexible, stretchable,
and biocompatible (Kim et al. 2012a). One recent study
incorporated a flexible mesh-like array of electrical sen-
sors that formed an interpenetrating network with a 3D
scaffold (Fig. 3C). Subsequent culturing of neurons showed
good viability over several weeks, and simultaneous
recordings of electrical activity from different cells was
possible. This degree of seamless integration may have
occurred because the synthetic architectural elements
were comparable in size with the neurons. Future work
with increased densities of electrical sensors could poten-
tially be used to map out neural circuits (Alivisatos et al.
2013). One difficulty with this approach is the positioning
of each electrode to interface with specific cells of interest.
The mechanical forces exerted by cells to sense and
remodel their surroundings are extremely important for
understanding how they regulate cell and tissue function
(Nelson and Bissell 2006). This has been previously ex-
plored in the context of cells adhering to flat two-
dimensional (2D) substrates. Recently, there has been
increasing interest in measuring how cells interact with
3D microenvironments, which may be more physiologi-
cally relevant (Baker and Chen 2012). The forces applied
by cells to deform 3D scaffolds was quantified by tracking
the motion of tens of thousands of embedded fluorescent
nanoparticles (Fig. 3D; Legant et al. 2010). Remarkably,
they found that fibroblasts in 3D exerted strong traction
forces near the tips of extensions, analogous to forces
measured in 2D near lamellipodia. An important next
step will be to adapt this technique to systems more
reminiscent of the extracellular matrix (ECM), which
exhibit highly heterogeneous and dynamic architectures
(Even-Ram and Yamada 2005).
Finally, nanostructures can be used to directly measure
single-cell phenotypes. In particular, one source of cell-to-
cell variability is the cell cycle, driving growth dynamics
and division events (Snijder and Pelkmans 2011). Reso-
nating sensors were used tomeasure themass of adherent
cells over 50 h (Fig. 3E; Park et al. 2010). Alternatively,
a resonating sensor with suspended geometry was used to
measure the mass of suspended cells over 35 h (Fig. 3F;
Son et al. 2012). Remarkably, both groups observed that
growth rate is not constant but increases with increasing
cell size. These growth rates varied at certain checkpoints
in the cell cycle and also varied at the single-cell level
Figure 3. (A) Sequencing DNAwith hybrid biological–artificial
nanopores. (B) Measuring cell-secreted ROS using carbon nano-
tubes. (C) Electrophysiology in three-dimensonal (3D) scaffolds
using nanowire arrays. (D) Mechanical deformation of 3D scaf-
folds using traction force microscopy. (E) Growth of adherent cells
measured using microresonators. (F) Growth of cells in solution
measured using suspended mass resonators. Reprinted by permis-
sion from Macmillan Publishers Ltd. from Hall et al. (2010), Jin
et al. (2010), Legant et al. (2010), Son et al. (2012), and Tian et al.
(2012). Reproduced with permission from Park et al. (2010).
Wong et al.
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across the population. These techniques may help to
reveal mechanically driven feedback mechanisms used
to constrain variability and maintain homeostasis at the
cell and tissue level (Kafri et al. 2013).
Overall, nanostructures enable sensitive measure-
ments of single molecular and cellular behaviors, enabled
by sizes comparable with these biological building blocks
and enhanced optical, electronic, and mechanical char-
acteristics. Nevertheless, the general schemes described
here require close proximity to cells, which often raises
questions of biocompatibility for extended long-term mea-
surements. Moreover, these techniques require highly
specialized fabrication techniques as well as measurement
infrastructure. As such, they are currently much more ef-
fective for in vitro measurements compared with in vivo.
Divide and conquer: droplets for high-throughput biology
Another approach for accessing single-molecule dynam-
ics and single-cell heterogeneity is based on using micro-
fluidics to partition bulk solutions into smaller volumes
that contain discrete numbers of molecules or cells. For
example, droplets of aqueous solution can be formed with
volumes of;1 pL (1012 L) or;10-mm diameter. At these
small sizes, the effective concentration of reagents is
increased, and the diffusion distance is considerably de-
creased (Leamon et al. 2006; Vincent et al. 2010). This
may be transformative for high-throughput assays (;109
droplets per milliliter) where extremely large numbers of
reactions must be performed in parallel while efficiently
using expensive reagents (Guo et al. 2012; Schneider
et al. 2013).
One device is based on the electrical manipulation of
droplets on flat surfaces (digital microfluidics) (Wheeler
2008). A modular set of operations could be performed on
droplets, including moving, merging, mixing, splitting,
and dispensing from different reservoirs (Fig. 4A). This
scheme is particularly advantageous for solid-phase or
liquid–liquid extraction using nonaqueous solvents, which
are generally incompatiblewith conventional plasticmicro-
fluidic devices. For example, estrogen could be directly
extracted from 1 mL of tissue, blood, or serum in ;10 min
without user intervention, corresponding to a 1000-fold
reduction in sample volume and a 20-fold increase in speed
(Mousa et al. 2009). These analytes were then sensitively
quantified using mass spectrometry. Dried blood spots
could also be analyzed using a similar technique, avoiding
the issues of fouling and clogging that challenge channel-
based microfluidic devices (Jebrail et al. 2011).
Alternatively, a channel geometry was implemented
where droplets of aqueous solution are compartmental-
ized by an oil phase and lined up single file (Fig. 4B).
Libraries of droplets encoding different analytes such as
drug compounds, viruses, antibodies, or enzymes could
be screened against cells or other reactants (Guo et al.
2012). These droplets can be interrogated by fluorescence
and sorted at high speeds on the order of 108 droplets per
day. This technology was applied to the directed evolu-
tion of the enzyme horseradish peroxidase, which gener-
ated mutants with catalytic rates >10 times faster than
the parent, with a 1000-fold increase in speed and a 1
million-fold reduction in cost (Agresti et al. 2010). An-
other application is digital PCR, where DNA can be com-
partmentalized in the single-molecule limit and amplified
without bias (Baker 2012). One challenge for droplet
microfluidics is to interface with the macroscopic world,
whether to isolate individual droplets of interest or for
highly combinatorial assays (Guo et al. 2012). One possi-
bility to address these difficulties could be the use of on-
chip logic and computation (Prakash and Gershenfeld
2007) for large-scale integration (Melin and Quake 2007).
Finding a needle in a haystack: extreme clinical diagnostics
Blood and other biofluids encode a tremendous amount of
information about the healthy or diseased state of pa-
tients (Toner and Irimia 2005). Unlike in vitro measure-
ments, deciphering clinically relevant information often
requires isolating certain biomarkers from an extraordi-
narily complex and heterogeneous mixture of proteins
(Anderson and Anderson 2002) or cells (Mach et al. 2013).
These biomarkers of interest may be extremely rare and
obscured by the complex background of the overall pop-
ulation.Moreover, effective point-of-care diagnosticsmust
be rapid, accurate, and low cost to serve patients and
inform clinical diagnostics (Chin et al. 2012). Nanostruc-
tures are advantageous, since their high surface areas can
be used to capture clinically relevant biomarkers through
molecular recognition processes. The enhanced chemical
and physical properties can be then be used to detect or
isolate these biomarkers.
Rapid, multiplexed proteomic analysis has been dem-
onstrated from microliter quantities of blood using in-
tegrated microfluidic chips (Fan et al. 2008). A robust and
modular patterning scheme was developed where non-
overlapping sets of DNA linkers immobilize antibodies at
discrete locations (Fig. 5A). The highly reproducible
patterning of these biomolecules at high density was
Figure 4. (A) One-picoliter droplets can be dispensed, moved,
merged, mixed, and split in an open geometry using electric
fields. (B) Droplet libraries can be challenged against a reactant
and then sorted at ultrahigh throughput in channels. From
Wheeler (2008). Reprinted with permission from AAAS. Repro-
duced from Guo et al. (2012) with permission of The Royal
Society of Chemistry.
Nanotechnology for biomedicine
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critical to achieve this multiplexed readout. These anti-
bodies are then used in a sandwich assay with a secondary
antibody, allowing measurement of twelve separate bio-
markers with high dynamic range. The correlations in
cytokine, growth factor, and antigen expression could be
used to stratify patient disease state. This approach was
also applied to measure secreted signals from immune
cells, revealing high functional heterogeneity at the single-
cell level (Ma et al. 2011).
Microvesicles secreted from tumors have also been char-
acterized as biomarkers (Shao et al. 2012). Microvesicles
were labeled using clusters of target-specificmagnetic nano-
particles, which could be sensitively detected using micro-
NMR (nuclear magnetic resonance) technology based on
changes in spin–spin relaxation time (T2) (Fig. 5B; Lee et al.
2008). This approach revealed striking heterogeneity in
single microvesicles compared with the bulk analyses that
have historically been performed. Remarkably, the proteo-
mic signature of these microvesicles was consistent with
the cells of origin. Furthermore, microvesicle expression
profiles tracked efficacy of drug treatment and were pre-
dictive of differences in treatment mechanisms.
Circulating tumor cells (CTCs) shed by metastatic
tumors into the blood have generated much recent inter-
est. However, CTCs are extremely rare, intermixed with
blood cells at concentrations of approximately one per
billion in clinical samples (Yu et al. 2011). An established
biomarker for CTCs is EpCAM, which is expressed by
cells of epithelial origin but lacking in blood cells. One
approach for ‘‘CTC-Chips’’ was based on the enhanced
surface area associated with micro/nanostructures for
adhesion-based capture using arrays of EpCAM-function-
alized micropillars (Nagrath et al. 2007). This technology
was clinically validated for tracking disease progression
and informing therapeutic treatments (Maheswaran et al.
2008). Nevertheless, one difficulty posed by laminar fluid
flow at these length scales is relatively slow mixing
(Stone et al. 2004), which limited the transport of CTCs
to the capture surface. The second generation ‘‘HB-Chip’’
addressed this issue by using topographically patterned
‘‘herringbones’’ to promote chaotic mixing (Stott et al.
2010). Remarkably, this technology also captured multi-
cellular CTC ‘‘clusters,’’ raising the possibility that col-
lective or cooperative behaviors may be advantageous
for metastatic dissemination. Additional texturing of the
capture surface using silicon nanowires has also demon-
strated excellent capture efficiencies (Wang et al. 2011b).
The third-generation CTC-iChip was based on the
separation of cells bound with ferromagnetic nanopar-
ticles (Ozkumur et al. 2013). This approach was highly
controlled using deterministic particle ordering through
inertial focusing (Di Carlo et al. 2007), allowing precise
deflection of selected cells into collection channels (Fig. 5C)
at extremely high throughput (8 mL/h; 107 cells/sec). The
small size of these nanoparticles is advantageous for
binding efficiently to surface receptors on CTCs—even
those with relatively low expression that may not be
captured using existing immunoaffinity techniques. Fur-
thermore, a negative depletion approach enriches for
cancer cells that do not express established epithelial cell
surface markers, including triple-negative breast cancers,
pancreatic cancers, and melanoma. These isolated CTCs
displayed morphological similarities to tumors of origin
but considerable variability in size. This single-cell het-
erogeneity was further interrogated by multigene micro-
fluidic quantitative RT–PCR of 15 different prostate cancer
Figure 5. (A) Integrated barcode chip for proteomic biomarkers from blood. (B) Protein typing of circulating microvesicles using
miniaturized NMR. (C) Antigen-dependent and -independent enrichment of rare tumor cells using magnetic nanoparticles. (D)
Multiplexed synthetic biomarkers are amplified by enzymatic cleavage near tumors followed by renal concentration for noninvasive
monitoring of disease progression. Reprinted by permission fromMacmillan Publishers Ltd. from Fan et al. (2008) and Shao et al. (2012).
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cells, revealing distinct subsets with variable expression of
epithelial, mesenchymal, and stem cell biomarkers as well
as androgen receptors. This approach is highly promising
for monitoring and guiding personalized therapies.
One unresolved question for biomedical diagnostics
is how early biomarkers can be detected during disease
progression. Recently, a quantitative framework was pro-
posed for estimating measurable levels of biomarker
based on their secretion from tumors (relative to healthy
tissues), transport into vasculature, and subsequent di-
lution, degradation, and elimination (Hori and Gambhir
2011). A troubling conclusion was a sizable mismatch
between tumor size and detection limits, translating to a
period of years before a tumor could be diagnosed.
A new approach was recently demonstrated for ampli-
fying biomarkers so that they can be more easily detected
(Kwong et al. 2013). A library of synthetic, mass-encoded
peptides was linked to nanoparticles using protease-
cleavable linkers (Fig. 5D). During liver fibrosis or co-
lorectal cancer, increased expression of proteases such as
matrix metalloproteins (MMP) led to repeated catalytic
cleavage of synthetic linkers, leading to liberation and
concentration of peptides in the urine. Samples were then
tested using mass spectroscopy for highly sensitive mea-
surements of the mass-encoded ‘‘synthetic biomarkers.’’
This scheme overcomes the limitations of conventional
biomarker detection by amplifying the initial signal, in-
creasing sensitivity using stable synthetic peptides that
do not occur biologically (low background), and multi-
plexing. This initial demonstration in small animals
shows great promise for further clinical applications with
humans.
The integration of microfluidics and nanotechnology
has enabled new modalities for point-of-care diagnostics
as well as implantable devices for monitoring patients,
particularly for early detection and to measure drug
efficacy. In particular, microfluidic technologies with
integrated sensors for processing bodily fluids such as
blood or saliva can be manufactured very reliably in a
high-throughput format and also are very robust. Nano-
structures, by virtue of their small dimensions, can
interact precisely with molecular and cellular compo-
nents as well as exhibit exceptional electronic, magnetic,
and optical properties. As a consequence, nanostructures
can considerably enhance the sensitivity of these assays.
However, these nanostructures may require highly spe-
cialized production techniques that are difficult to scale
up (Box 1). A crucial challenge for the future will be to
translate these technologies to the bedside or point of care
with sufficiently high accuracy and low cost.
Lying on a bed of nails: minimally invasive delivery
using nanoneedles
A continuing challenge for therapeutic applications is
targeted delivery of agents to defined locations in cells
and tissues. Biological barriers such as the cell mem-
brane, mucosal layers, or skin have evolved to be highly
efficient at excluding unrecognized materials. For in-
stance, eukaryotic cell membranes partition the interior
of a cell from the surrounding extracellular environment
and are comprised of amphiphilic lipids with a hydro-
philic head and a hydrophobic tail (De Weer 2000). These
lipids are arranged to form a hydrophobic core region that
restricts the transport of hydrophilic and polar molecules
across the bilayer. As a consequence, using such mole-
cules to perturb cellular function often requires special
techniques to bypass the cell membrane, such as electro-
poration or delivery agents, whichmay have a detrimental
effect on cell viability. As a consequence, molecular agents
such as plasmid DNA, siRNA, peptides, proteins, and
small molecule drugs may be ineffective when delivered
systemically. Nanostructures with small diameters but
a high aspect ratio are a highly promising alternative for
bypassing these barriers in order to deliver agents to
defined locations.
A nanopatterned surface consisting of an array of silicon
nanowires with an ;50-nm diameter and ;1-mm height
was functionalized with a variety of molecular agents in
a microarray format (Shalek et al. 2010, 2012). Remark-
ably, these nanowires spontaneously inserted into cells
without inducing apoptosis (Fig. 6A). This led to robust
delivery of molecular agents (>95%) into the cellular in-
terior to guide neuronal growth, siRNA knockdown, and
Figure 6. (A) Arrays of silicon nanowires can deliver siRNA into
the interior of dendritic cells. Dissolving polymer microneedles
(B) can deliver influenza vaccine to defined locations beneath the
skin (C). Reprinted by permission from Macmillan Publishers
Ltd. from Sullivan et al. (2010). Reprinted with permission from
Shalek et al. (2012).  2012 American Chemical Society.
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inhibition of apoptosis as well as target proteins to
organelles. These nanopatterned surfaces are fully com-
patible with existing printing technologies, enabling
‘‘living-cell microarrays’’ for high-throughput screens
of cell stimuli with greatly increased efficiency. Never-
theless, one limitation of this technique is that the
concentration and release kinetics of drugs are not well
controlled. An alternate approach was based on an array
of hollow alumina ‘‘nanostraws’’ that served as fluid
conduits from an adjacent reservoir (VanDersarl et al.
2012). The composition of molecular species in the
reservoir could be defined using microfluidics, allowing
spatial gradients or transient pulses of molecular spe-
cies. Further control over molecular delivery and in-
tracellular transport was achieved by applying spatially
localized electrical pulses, which enabled >70% trans-
fection efficiency (Xie et al. 2013). Future work will be
necessary to explore the role of physical nanotopography
on cell behavior (Kim et al. 2012b) as well as confirm
long-term cell viability.
Human skin also displays barrier properties that limit
molecular transport (Prausnitz et al. 2004). The outermost
layer of the epidermis, known as the stratum corneum,
displays a high degree of structural heterogeneity. As
a consequence, molecular transport across this layer
must occur through highly tortuous pathways and can
be strongly impeded. One approach to deliver molecular
agents is to use hypodermic needles that inject past the
stratum corneum. However, this is a painful, highly in-
vasive process that cannot be self-administered. Instead,
an array of polymeric microneedles with a smaller di-
ameter can painlessly insert into skin, delivering drugs to
a controlled depth (Fig. 6B,C; Sullivan et al. 2010). This is
particularly useful for vaccination, since immunogenic
Langerhans cells are often localized ;100 mm from the
surface. These microneedles degrade within minutes, al-
lowing the skin to reseal and recover barrier function to
prevent infection. Moreover, these microneedles were
found to improve on antibody and cellular immune
response in mice compared with conventional needles.
Variations on this concept include multilayer-coated
microneedles, which can be used for programmed and
sustained delivery profiles (DeMuth et al. 2013).
Deliver to zip code: multifunctional nanoparticles
for therapy and diagnostics
Drug-loaded nanoparticles can also be advantageous
for delivering concentrated doses to target sites through
prolonged circulation times and increased uptake com-
bined with reduced toxicity elsewhere (Shi et al. 2010).
Size appears to play an important role in spherical particle
transport, since micrometer-scale particles are often
cleared by macrophage phagocytosis or filtration in the
liver or spleen (Mitragotri and Lahann 2009). Neverthe-
less, these behaviors are also affected by physical charac-
teristics such as shape, mechanics, and surface chemistry
(Nel et al. 2009). For example, pathogens such as bacteria
and viruses display distinctive asymmetric and aniso-
tropic shapes, which enable specific interactions with
target cells and evasion of the immune response (Yoo
et al. 2011). In contrast, red blood cells exhibit a charac-
teristic flexible, discoidal shape that avoids filtration in
the spleen, despite their relatively large size (Skalak and
Branemark 1969). Inspired by this physical phenomenon,
long, flexible polymeric micelles were designed that
persist in circulation for extended periods with minimal
phagocytosis (Geng et al. 2007). Recent advances in synthe-
sis and fabrication have enabled the design of biomimetic
nanosystems that can cooperate to synergistically improve
their functionality (Box 1).
Nanoparticles can also incorporate advanced function-
ality such as targeting to specific organs and cells, re-
sponsiveness to external stimuli, imaging capabilities,
and drug delivery (Bao et al. 2013). For example, passive
targeting of tumors based on enhanced permeability and
retention (EPR) in ‘‘leaky vasculature’’ (Chauhan et al.
2011) can be complimented by ‘‘active’’ targeting of cancer
cells. For instance, tumor cells and vasculature often
display distinct molecular ‘‘zip codes’’ that can be targeted
by short peptide sequences (Ruoslahti 2012). Remarkably,
certain peptides can actually penetrate deep into tissues,
thereby overcoming elevated interstitial pressures (Sugahara
et al. 2009). These findings, which originated in phage dis-
play and further developed through the imaging of tar-
geted nanomaterials, have led to new fundamental insights
on the trafficking of particulate materials in vivo, termed
the CendR pathway (Teesalu et al. 2009).
This approach was clinically translated as a nanopar-
ticle that uses a targeting ligand for serum membrane
antigen (PSMA) (Fig. 7A; Hrkach et al. 2012). This nano-
particle incorporates a ‘‘stealth’’ polymer brush shell that
limits immunosurveilance as well as a degradable hydro-
phobic core that could be loaded with drugs. These
optimized characteristics promoted circulation times
while reducing liver accumulation. Moreover, these nano-
particles exhibited increased tumor accumulation relative
to solvent-based drugs and prolonged tumor suppression.
In preliminary patient trials, tumor shrinkage was ob-
served even at diminished dosages of nanoparticles rela-
tive to solvent-based drugs.
A particularly challenging but attractive therapeutic
cargo is siRNA. In principle, it can silence so-called
‘‘undruggable’’ targets but must be delivered repeatedly
to the cytosol of the target cell to engage the silencing
machinery in the RNA-induced silencing complex (RISC)
(Whitehead et al. 2009). Moreover, siRNA is vulnerable
to degradation by serum nucleases and renal filtration.
Nanomaterials have the potential to address these issues
by enabling targeted delivery of enhanced payloads while
protecting the siRNA until needed (Davis et al. 2008).
Exciting early clinical results have been demonstrated in
cancer patients using a synthetic delivery based on a
transferrin-targeted cyclodextran particle with a ‘‘stealth’’
polymer brush shell (Davis et al. 2010). Recently, tumor-
penetrating nanocomplexes exploiting the CendR path-
way have been developed to target essential oncogenes
such as ID4 (Ren et al. 2012). An important next step will
be to enhance the potency of siRNA, which has been
demonstrated through the addition of lipid-like nano-
Wong et al.
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materials, enabling the silencing of multiple genes si-
multaneously (Love et al. 2010). It should be noted that
nanomaterials have been used extensively to silence
targets related to liver function, including for liver cancer,
hypercholesterolemia, diabetes II, HBV, etc. (Whitehead
et al. 2009) Nevertheless, additional work will be needed
to extend delivery platforms beyond the liver and tumors
to other normal and diseased tissues.
One unresolved issue is whether the additional func-
tionality of these nanoparticles has trade-offs by increas-
ing manufacturing complexity and the likelihood of
unforeseen effects in vivo (Cheng et al. 2012). For in-
stance, loading multiple drugs may result in cross-
reactivity and difficulties in coordinating release profiles.
Alternatively, given the finite volume available in a nano-
particle, loading both imaging and therapeutic agents
may mean diminished effectiveness due to insufficient
quantities of both. Rather that increase the complexity of
individual nanoparticles, researchers have designed co-
operative nanosystems where the action of simple, spe-
cialized particles are spatially and temporally coordinated.
One approach relies on nanoparticles that can communi-
cate through the environment to amplify the recruitment
of therapeutics to a tumor site (von Maltzahn et al. 2011).
In this system, gold nanorods passively accumulate in
tumors, where they activate a coagulation response upon
heating (Fig. 7B). This coagulation serves as a ‘‘signal’’ for
‘‘receiver’’ nanoparticles that target the transglutaminase
or polymerized fibrin present in the coagulated environ-
ment. This communication enhances accumulation of
receiving nanoparticles by 40-fold relative to noncom-
municating controls, corresponding to an amplification
of 35,000 molecules per signaling entity. In a similar
manner, a two-particle system was designed with one
nanoparticle increasing tumor permeability upon heating
and inducing stress-related up-regulation of p32 surface
receptors (Park et al. 2010). These receptors were then
targeted by a second doxorubicin-loaded liposome, thereby
amplifying therapeutic delivery to the permeated tumor.
Such cooperative, synergistic behaviors offer an alterna-
tive route for the design of new therapeutic strategies.
Discussion
Nanotechnology offers exciting new approaches for both
measuring living systems, including characterizing dis-
tinctive phenotypes and enriching clinically relevant
biomarkers, and perturbing living systems, such as tar-
geted drug delivery modalities that can overcome biolog-
ical barriers. These various examples can be generalized as
structural or functional interfaces for communicating in-
formation between biotic and abiotic systems. In this
context, several key themes emerge that motivate the
ongoing development of nanotechnology for biology and
medicine. First, nanotechnology enables interfaces be-
tween the macroscale of humans down to the nanoscale
ofmolecules and cells. These tools can be used to precisely
examine and perturb individuals within a population,
rather than the relatively crude bulk methods that have
been used historically. Second, nanotechnology is based
on translation and conversion between different types of
signals. For example, cells and tissues often signal using
biochemical messengers in ionic solution, which is very
different from the conventional technologies used by
humans. Nevertheless, the exceptional chemical and
physical properties of nanomaterials, including enhanced
electronic, optical, and thermal functionality, can be
used to locally detect or perturb biological phenomena.
Finally, many biomedical applications require the
compatibility of artificial nanomaterials with biologi-
cal systems. Artificial nanomaterials are often synthe-
sized and fabricated under conditions that are highly
toxic to cells and tissues. Thus, these artificial nano-
materials may not function as designed under complex
physiological conditions. Maintaining the structure
and function of both artificial and biological elements
over extended time periods remains an ongoing area of
research.
Moving forward, translating these proof-of-concept
technologies from a controlled laboratory environment
to widespread usage will require extensive testing and
validation. In particular, biomedical diagnostics have
to meet relatively high standards for performance and
accuracy, especially compared with existing technolo-
gies. Another challenge is manufacturing, since nano-
technological systems are often synthesized or fabri-
cated using highly specialized techniques that are not
amenable for commercial scale-up. One approach, rem-
Figure 7. (A) Nanoparticle consisting of a degradable polymeric
core loaded with drugs protected by a ‘‘stealth’’ polymer brush
shell with targeting ligands. (B) Amplified targeting of nano-
particles by locally induced coagulation. From Hrkach et al.
(2012). Reprinted with permission from AAAS. Reprinted by
permission from Macmillan Publishers Ltd. from von Maltzahn
et al. (2011).
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iniscent of synthetic biology (Cheng and Lu 2012), is to
begin standardization of nanotechnological ‘‘parts,’’ which
would enable the ease of comparison between different
studies as well as integration of these different modular
components.
Finally, as artificial nanotechnologies become in-
creasingly capable of interacting with each other and
their biological counterparts, the resulting behaviors
may be highly unpredictable and counterintuitive.
For example, signaling and feedback mechanisms be-
tween the artificial and biological systems may gener-
ate emergent behaviors that would not be observed
otherwise. Nonetheless, harnessing this complexity
can enable cooperative systems capable of performing
tasks beyond the individual functionalities of the con-
stituent parts. For instance, under the proper conditions,
biomimetic behaviors could occur, such as amplifica-
tion, optimization, mapping, self-assembly, collective
motion, synchronization, and decision-making. Ulti-
mately, a systems approach (Csete and Doyle 2002) to
model the interactions between artificial and biological
systems may aid in understanding modularity, robustness,
and fragility, which could inform biological investigations
and guide new therapeutic strategies.
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